2023年6月23日

新聞稿IRBM延伸肽治療與默克& Co . Inc .)合作的法律美國新澤西新聞稿IRBM延伸肽治療與默克& Co . Inc .)合作的法律新澤西美國2023年6月22日,羅馬,意大利——IRBM,一個創新的合同研究組織,今天宣布,已經與默克公司簽署了一項新的協議& Co . Inc .)的法律美國新澤西,稱為默沙東-在美國和加拿大以外,肽治療領域繼續合作。“這種合作的成功體現的優秀成果交付可用的口頭肽候選人,”伊麗莎白·比安奇說高級IRBM肽化學主管。“我們很高興繼續這種合作作為我們的使命的一部分促進有效的代理到診所。“IRBM首席科學官卡洛Toniatti說:“我們將感到無比驕傲IRBM一流的科學專業知識的設計和合成肽與默克公司& Co . Inc .)特殊藥物開發能力專注於交付創新療法患者需要”。“在默沙東公司,我們繼續評估跨多個適應症肽鏈型治療候選人的機會,”羅伯Garbaccio說,發現化學主管副總裁MSD研究實驗室。“我們期待繼續我們富有成效的合作與我們的同事IRBM在這個引人注目的研究領域。“近年來,取得了顯著的進步通過行之有效的噬菌體肽的發現和mRNA顯示平台和半衰期的重大進展實現了擴展策略和製定增強劑的使用口服途徑支持政府。利用這些新技術的合作開發肽候選人進展到診所。IRBM建立了廣泛的多肽藥物開發方麵的專業知識。建立集成平台覆蓋整個範圍的活動需要發現和開發新型肽為優化先導物。 The delivery of safe and effective candidate peptide drugs is supported by the use of phage display peptide libraries for hit identification, advanced synthetic strategies from macrocycles to proteins, molecular design and engineering, structural biology, biochemical, biophysical and cell-based assay to enable structural activity relationship studies as well as in vitro and in vivo ADME studies. Background Information IRBM IRBM is an innovative contract research organization working across all aspects of drug discovery and early development for different modalities – small molecules, peptides, and antibodies. We foster collaborations with organizations from the pharmaceutical, biotech and academic sectors to accelerate drug discovery from target validation and hit identification to candidate nomination. Our multidisciplinary team work at a state-of-the-art R&D facility near Rome where projects are carried out “under one roof” enabling rapid cycle times and close integration of the scientific teams. IRBM’s scientists have discovered several drugs that are on the market, and more than 25 compounds have gone into clinical testing. The company was founded in 2010, as a spin-off from Merck & Co. Rahway NJ USA. Now in our 14th year as an independent research organisation, we have laid the foundations to become a global centre for excellence in all aspects of drug discovery and early development. Media contact